AbbVie Inc. (ABBV) vs REGENERON PHARMACEUTICALS, INC. (REGN)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | ABBV | REGN |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $61.16B | $14.34B |
| Revenue growth (YoY) | ▲ 8.6% | ▲ 1.0% |
| Net income | $4.23B | $4.5B |
| Gross margin | 70.2% | — |
| Diluted EPS | $2.36 | $41.48 |
| Insider net (6 mo) | +12.3K sh • 1 sells • 0 buys | +2.3K sh • 7 sells • 0 buys |
| Institutional owners | 46 | 45 |
| Institutional value held | $222.87B | $38.9B |
| Next earnings (est.) | Around Feb 3, 2027 | Around Jan 11, 2027 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About AbbVie Inc. (ABBV)
AbbVie Inc., incorporated in Delaware in 2012, is a global, diversified research-based biopharmaceutical company that became an independent, publicly-traded entity on January 1, 2013, following its spin-off from Abbott Laboratories. Read more →
About REGENERON PHARMACEUTICALS, INC. (REGN)
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular… Read more →
Source: SEC EDGAR.